 to VLUs remain controversial
with little consensus in published studies. The initial pivotal
trial for Apligraf allowed up to ﬁve applications of the product during the ﬁrst 3 weeks of the study.259 Reapplication
was performed if the investigator thought that there was
less than 50% “take” of the skin equivalent on inspection
of the wound. Subsequent to this clinical trial, it has
been determined that living skin equivalents do not persist